Given the wide distribution of the renin–angiotensin system in the cardiovascular system and in the heart, it is not surprising that angiotensin-converting enzyme inhibitors and angiotensin receptor blockers have become key first line therapeutic interventions in heart failure. The gene discussed is ACE; the disease is heart failure.